Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 16/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 16/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6553244 | 0.88 | PDE4A (0.73) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2459219 | 0.86 | PDE4A (0.68) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7433881 | 0.83 | TNF (0.68) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2459256 | 0.83 | PDE4B (0.61) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL23000632 | 0.82 | TNF (0.75) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1193538 | 0.82 | PDE4B (0.78) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15198844 | 0.82 | PDE4B (0.78) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29651471 | 0.82 | PDE4B (0.78) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23000615 | 0.82 | TNF (0.75) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6098123 | 0.82 | TNF (0.75) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026269-B2 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090148388-A1 | Isoindoline Compounds and Methods of Making and Using the Same | CELGENE CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-7495112-B2 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070244183-A1 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION | 2007-10-18 | — | — | US | disclosed |
| US-7244759-B2 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1778635-A2 | ISOINDOLINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CELGENE CORPORATION (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084815-A1 | Isoindoline compounds and methods of making and using the same | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006025991-A2 | ISOINDOLINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CELGENE CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090148388-A1 | Isoindoline Compounds and Methods of Making and Using the Same | MCL1, HPGDS, TPMT | TNF 216/4885PDE4A 1112/4885PDE4B 1194/4885 |
| US-20070244183-A1 | Isoindoline compounds and methods of making and using the same | MCL1, HPGDS, TPMT | TNF 216/4885PDE4A 1112/4885PDE4B 1194/4885 |
| US-20060084815-A1 | Isoindoline compounds and methods of making and using the same | MCL1, HPGDS, TPMT | TNF 216/4885PDE4A 1112/4885PDE4B 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.